Medivir´s licensee, Tango Therapeutics, has discontinued development of its TNG348 clinical program

https://news.cision.com/medivir/r/medivir-s-licensee--tango-therapeutics--has-discontinued-development-of-its- tng348-clinical-program,c3987012 STOCKHOLM, May 23, 2024 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announced today that Medivir's licensee, Tango Therapeutics (NASDAQ: TNGX; Tango), has announced that the phase 1/2 clinical trial of TNG348, a novel USP1 inhibitor, is being ...